Bioengineered Protein Drugs Market : Global Industry Analysis and forecast (2023 to 2029)


Bioengineered Protein Drugs Market is expected to reach US$ 5.02 Mn. at a CAGR of 4.5 during the forecast period 2029.

Bioengineered Protein Drugs Market Drivers and Restrains

Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic proteins. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bio reactivity and success rate in treating life-threatening diseases and injuries. Bioengineered protein drugs are the major factors conducting the biological process and come up with the efficient therapeutic agents. The bioengineered protein drug includes wide-ranging products such as hormones, vaccines, cytokines, and monoclonal antibodies. Rising patient population with diseases such as cancer, heart diseases, diabetes, and asthma are fueling the global bioengineered protein drugs market. High manufacturing cost and Complications in treatment of numerous diseases with these drugs hamper growth of bioengineered protein drugs market globally. Furthermore, novel techniques in manufacturing of bioengineering drug proteins aimed at the specific drug delivery and drug combinations for increasing efficiency of product are the factors driving global market.Bioengineered Protein Drugs Market

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Bioengineered Protein Drugs Market key segmentation

Bioengineered Protein Drugs Market is segmented into type and Disease condition. Based on type market is further categorized as Monoclonal Antibodies, Therapeutic Proteins and Vaccines. Monoclonal Antibodies is further sub-divided in to Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis. And Therapeutic Proteins segment into Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytic. Among them, the therapeutic protein segment leads with highest share of Bioengineered Protein Drugs Market in 2022. Because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products.

Bioengineered Protein Drugs Market Regional Analysis

Based on region, the bioengineered protein drugs market is divided into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America dominated the Bioengineered Protein Drugs Market in 2018. Rising instances of cancer and emergence of innovative protein therapeutics for treatment of cancer are responsible for increased growth rate in this region. Europe holds 2nd highest share of global Bioengineered Protein Drugs market. Increased R&D spending, along with increasing competition, patent expiries and new technologies are the factors propelling global market in this region. Asia Pacific region is expected to register highest growth rate in the global bioengineered protein drug market owing to the factors such as developing economic market scenario and developing research sector.

The objective of the report is to present comprehensive analysis of Global Bioengineered Protein Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Bioengineered Protein Drugs Market dynamics, structure by analyzing the market segments, and project the Global Bioengineered Protein Drugs Market size. Clear representation of competitive analysis of key players by Bioengineered Protein Drugs Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Bioengineered Protein Drugs Market make the report investor’s guide.

Bioengineered Protein Drugs Market Scope: Inquire before buying






Bioengineered Protein Drugs Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 3.68 Mn.




Forecast Period 2023 to 2029 CAGR:
4.5%
Market Size in 2029:
US $ 5.02 Mn.




 Segments Covered:
by type
• Monoclonal Antibodies
• Therapeutic Proteins
• Vaccines




by Disease Condition
• Cancer
• Diabetes
• Autoimmune Disorder
• Infectious Disease
• Hematopoiesis
• CVD
• Neurodegenerative






Bioengineered Protein Drugs Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Key players operating on Bioengineered Protein Drugs Market

• Abbott India Ltd.;
• Amgen, Inc.;
• Bayer AG;
• Biocon Ltd.;
• Dr. Reddy’s Laboratories Ltd.;
• Eli Lilly and Company;
• F. Hoffmann Roche AG;
• GlaxoSmithKline PLC;
• Johnson & Johnson;
• Merck & Co., Inc.;
• Novartis International AG;
• Panacea Biotec Ltd.;
• ProBioGen AG
• Reliance Life Sciences Pvt. Ltd.
• AbbVie Inc.
• Sanofi S.A.
• Novo Nordisk AG
• ProBioGen AG
• Fresenius Kabi USA

Frequently Asked Questions:

1. Which region has the largest share in Global Bioengineered Protein Drugs Market?
Ans: Europe region held the highest share in 2022.

2. What is the growth rate of Global Bioengineered Protein Drugs Market?
Ans: The Global Bioengineered Protein Drugs Market is growing at a CAGR of 4.5% during forecasting period 2023-2029.

3. What is scope of the Global Bioengineered Protein Drugs Market report?
Ans: Global Bioengineered Protein Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Bioengineered Protein Drugs Market?
Ans: The important key players in the Global Bioengineered Protein Drugs Market are – Abbott India Ltd., Amgen, Inc., Bayer AG, Biocon Ltd., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Panacea Biotec Ltd., ProBioGen AG, Reliance Life Sciences Pvt. Ltd., AbbVie Inc., Sanofi S.A., Novo Nordisk AG, ProBioGen AG, and Fresenius Kabi USA

5. What is the study period of this Market?
Ans: The Global Bioengineered Protein Drugs Market is studied from 2022 to 2029. 




Global Bioengineered Protein Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Bioengineered Protein Drugs Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Bioengineered Protein Drugs Market Analysis and Forecast
6.1. Global Bioengineered Protein Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Bioengineered Protein Drugs Market Analysis and Forecast, By Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Bioengineered Protein Drugs Market Value Share Analysis, By Type
7.4. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, By Type
7.5. Global Bioengineered Protein Drugs Market Analysis, By Type
7.6. Global Bioengineered Protein Drugs Market Attractiveness Analysis, By Type

8. Global Bioengineered Protein Drugs Market Analysis and Forecast, By Disease Condition
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
8.4. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, By Disease Condition
8.5. Global Bioengineered Protein Drugs Market Analysis, By Disease Condition
8.6. Global Bioengineered Protein Drugs Market Attractiveness Analysis, By Disease Condition

9. Global Bioengineered Protein Drugs Market Analysis, by Region
9.1. Global Bioengineered Protein Drugs Market Value Share Analysis, by Region
9.2. Global Bioengineered Protein Drugs Market Size (US$ Bn) Forecast, by Region
9.3. Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region

10. North America Bioengineered Protein Drugs Market Analysis
10.1. Key Findings
10.2. North America Bioengineered Protein Drugs Market Overview
10.3. North America Bioengineered Protein Drugs Market Value Share Analysis, By Type
10.4. North America Bioengineered Protein Drugs Market Forecast, By Type
10.4.1. Monoclonal Antibodies
10.4.2. Therapeutic Proteins
10.4.3. Vaccines
10.5. North America Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
10.6. North America Bioengineered Protein Drugs Market Forecast, By Disease Condition
10.6.1. Cancer
10.6.2. Diabetes
10.6.3. Autoimmune Disorder
10.6.4. Infectious Disease
10.6.5. Hematopoiesis
10.6.6. CVD
10.6.7. Neurodegenerative
10.7. North America Bioengineered Protein Drugs Market Value Share Analysis, by Country
10.8. North America Bioengineered Protein Drugs Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Bioengineered Protein Drugs Market Analysis, by Country
10.10. U.S. Bioengineered Protein Drugs Market Forecast, By Type
10.10.1. Monoclonal Antibodies
10.10.2. Therapeutic Proteins
10.10.3. Vaccines
10.11. U.S. Bioengineered Protein Drugs Market Forecast, By Disease Condition
10.11.1. Cancer
10.11.2. Diabetes
10.11.3. Autoimmune Disorder
10.11.4. Infectious Disease
10.11.5. Hematopoiesis
10.11.6. CVD
10.11.7. Neurodegenerative
10.12. Canada Bioengineered Protein Drugs Market Forecast, By Type
10.12.1. Monoclonal Antibodies
10.12.2. Therapeutic Proteins
10.12.3. Vaccines
10.13. Canada Bioengineered Protein Drugs Market Forecast, By Disease Condition
10.13.1. Cancer
10.13.2. Diabetes
10.13.3. Autoimmune Disorder
10.13.4. Infectious Disease
10.13.5. Hematopoiesis
10.13.6. CVD
10.13.7. Neurodegenerative
10.14. North America Bioengineered Protein Drugs Market Attractiveness Analysis
10.14.1. By Type
10.14.2. By Disease Condition
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Bioengineered Protein Drugs Market Analysis
11.1. Key Findings
11.2. Europe Bioengineered Protein Drugs Market Overview
11.3. Europe Bioengineered Protein Drugs Market Value Share Analysis, By Type
11.4. Europe Bioengineered Protein Drugs Market Forecast, By Type
11.4.1. Monoclonal Antibodies
11.4.2. Therapeutic Proteins
11.4.3. Vaccines
11.5. Europe Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
11.6. Europe Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.6.1. Cancer
11.6.2. Diabetes
11.6.3. Autoimmune Disorder
11.6.4. Infectious Disease
11.6.5. Hematopoiesis
11.6.6. CVD
11.6.7. Neurodegenerative
11.7. Europe Bioengineered Protein Drugs Market Value Share Analysis, by Country
11.8. Europe Bioengineered Protein Drugs Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Bioengineered Protein Drugs Market Analysis, by Country
11.10. Germany Bioengineered Protein Drugs Market Forecast, By Type
11.10.1. Monoclonal Antibodies
11.10.2. Therapeutic Proteins
11.10.3. Vaccines
11.11. Germany Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.11.1. Cancer
11.11.2. Diabetes
11.11.3. Autoimmune Disorder
11.11.4. Infectious Disease
11.11.5. Hematopoiesis
11.11.6. CVD
11.11.7. Neurodegenerative
11.12. U.K. Bioengineered Protein Drugs Market Forecast, By Type
11.12.1. Monoclonal Antibodies
11.12.2. Therapeutic Proteins
11.12.3. Vaccines
11.13. U.K. Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.13.1. Cancer
11.13.2. Diabetes
11.13.3. Autoimmune Disorder
11.13.4. Infectious Disease
11.13.5. Hematopoiesis
11.13.6. CVD
11.13.7. Neurodegenerative
11.14. France Bioengineered Protein Drugs Market Forecast, By Type
11.14.1. Monoclonal Antibodies
11.14.2. Therapeutic Proteins
11.14.3. Vaccines
11.15. France Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.15.1. Cancer
11.15.2. Diabetes
11.15.3. Autoimmune Disorder
11.15.4. Infectious Disease
11.15.5. Hematopoiesis
11.15.6. CVD
11.15.7. Neurodegenerative
11.16. Italy Bioengineered Protein Drugs Market Forecast, By Type
11.16.1. Monoclonal Antibodies
11.16.2. Therapeutic Proteins
11.16.3. Vaccines
11.17. Italy Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.17.1. Cancer
11.17.2. Diabetes
11.17.3. Autoimmune Disorder
11.17.4. Infectious Disease
11.17.5. Hematopoiesis
11.17.6. CVD
11.17.7. Neurodegenerative
11.18. Spain Bioengineered Protein Drugs Market Forecast, By Type
11.18.1. Monoclonal Antibodies
11.18.2. Therapeutic Proteins
11.18.3. Vaccines
11.19. Spain Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.19.1. Cancer
11.19.2. Diabetes
11.19.3. Autoimmune Disorder
11.19.4. Infectious Disease
11.19.5. Hematopoiesis
11.19.6. CVD
11.19.7. Neurodegenerative
11.20. Rest of Europe Bioengineered Protein Drugs Market Forecast, By Type
11.20.1. Monoclonal Antibodies
11.20.2. Therapeutic Proteins
11.20.3. Vaccines
11.21. Rest of Europe Bioengineered Protein Drugs Market Forecast, By Disease Condition
11.21.1. Cancer
11.21.2. Diabetes
11.21.3. Autoimmune Disorder
11.21.4. Infectious Disease
11.21.5. Hematopoiesis
11.21.6. CVD
11.21.7. Neurodegenerative
11.22. Europe Bioengineered Protein Drugs Market Attractiveness Analysis
11.22.1. By Type
11.22.2. By Disease Condition
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Bioengineered Protein Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Bioengineered Protein Drugs Market Overview
12.3. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, By Type
12.4. Asia Pacific Bioengineered Protein Drugs Market Forecast, By Type
12.4.1. Monoclonal Antibodies
12.4.2. Therapeutic Proteins
12.4.3. Vaccines
12.5. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
12.6. Asia Pacific Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.6.1. Cancer
12.6.2. Diabetes
12.6.3. Autoimmune Disorder
12.6.4. Infectious Disease
12.6.5. Hematopoiesis
12.6.6. CVD
12.6.7. Neurodegenerative
12.7. Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Country
12.8. Asia Pacific Bioengineered Protein Drugs Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Bioengineered Protein Drugs Market Analysis, by Country
12.10. China Bioengineered Protein Drugs Market Forecast, By Type
12.10.1. Monoclonal Antibodies
12.10.2. Therapeutic Proteins
12.10.3. Vaccines
12.11. China Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.11.1. Cancer
12.11.2. Diabetes
12.11.3. Autoimmune Disorder
12.11.4. Infectious Disease
12.11.5. Hematopoiesis
12.11.6. CVD
12.11.7. Neurodegenerative
12.12. India Bioengineered Protein Drugs Market Forecast, By Type
12.12.1. Monoclonal Antibodies
12.12.2. Therapeutic Proteins
12.12.3. Vaccines
12.13. India Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.13.1. Cancer
12.13.2. Diabetes
12.13.3. Autoimmune Disorder
12.13.4. Infectious Disease
12.13.5. Hematopoiesis
12.13.6. CVD
12.13.7. Neurodegenerative
12.14. Japan Bioengineered Protein Drugs Market Forecast, By Type
12.14.1. Monoclonal Antibodies
12.14.2. Therapeutic Proteins
12.14.3. Vaccines
12.15. Japan Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.15.1. Cancer
12.15.2. Diabetes
12.15.3. Autoimmune Disorder
12.15.4. Infectious Disease
12.15.5. Hematopoiesis
12.15.6. CVD
12.15.7. Neurodegenerative
12.16. ASEAN Bioengineered Protein Drugs Market Forecast, By Type
12.16.1. Monoclonal Antibodies
12.16.2. Therapeutic Proteins
12.16.3. Vaccines
12.17. ASEAN Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.17.1. Cancer
12.17.2. Diabetes
12.17.3. Autoimmune Disorder
12.17.4. Infectious Disease
12.17.5. Hematopoiesis
12.17.6. CVD
12.17.7. Neurodegenerative
12.18. Rest of Asia Pacific Bioengineered Protein Drugs Market Forecast, By Type
12.18.1. Blocks
12.18.2. Panels
12.18.3. Others
12.19. Rest of Asia Pacific Bioengineered Protein Drugs Market Forecast, By Disease Condition
12.19.1. Cancer
12.19.2. Diabetes
12.19.3. Autoimmune Disorder
12.19.4. Infectious Disease
12.19.5. Hematopoiesis
12.19.6. CVD
12.19.7. Neurodegenerative
12.20. Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis
12.20.1. By Type
12.20.2. By Disease Condition
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Bioengineered Protein Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Bioengineered Protein Drugs Market Overview
13.3. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, By Type
13.4. Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Type
13.4.1. Monoclonal Antibodies
13.4.2. Therapeutic Proteins
13.4.3. Vaccines
13.5. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
13.6. Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition
13.6.1. Cancer
13.6.2. Diabetes
13.6.3. Autoimmune Disorder
13.6.4. Infectious Disease
13.6.5. Hematopoiesis
13.6.6. CVD
13.6.7. Neurodegenerative
13.7. Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Country
13.8. Middle East & Africa Bioengineered Protein Drugs Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Bioengineered Protein Drugs Market Analysis, by Country
13.10. GCC Bioengineered Protein Drugs Market Forecast, By Type
13.10.1. Monoclonal Antibodies
13.10.2. Therapeutic Proteins
13.10.3. Vaccines
13.11. GCC Bioengineered Protein Drugs Market Forecast, By Disease Condition
13.11.1. Cancer
13.11.2. Diabetes
13.11.3. Autoimmune Disorder
13.11.4. Infectious Disease
13.11.5. Hematopoiesis
13.11.6. CVD
13.11.7. Neurodegenerative
13.12. South Africa Bioengineered Protein Drugs Market Forecast, By Type
13.12.1. Monoclonal Antibodies
13.12.2. Therapeutic Proteins
13.12.3. Vaccines
13.13. South Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition
13.13.1. Cancer
13.13.2. Diabetes
13.13.3. Autoimmune Disorder
13.13.4. Infectious Disease
13.13.5. Hematopoiesis
13.13.6. CVD
13.13.7. Neurodegenerative
13.14. Rest of Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Type
13.14.1. Monoclonal Antibodies
13.14.2. Therapeutic Proteins
13.14.3. Vaccines
13.15. Rest of Middle East & Africa Bioengineered Protein Drugs Market Forecast, By Disease Condition
13.15.1. Cancer
13.15.2. Diabetes
13.15.3. Autoimmune Disorder
13.15.4. Infectious Disease
13.15.5. Hematopoiesis
13.15.6. CVD
13.15.7. Neurodegenerative
13.16. Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis
13.16.1. By Type
13.16.2. By Disease Condition
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Bioengineered Protein Drugs Market Analysis
14.1. Key Findings
14.2. South America Bioengineered Protein Drugs Market Overview
14.3. South America Bioengineered Protein Drugs Market Value Share Analysis, By Type
14.4. South America Bioengineered Protein Drugs Market Forecast, By Type
14.4.1. Monoclonal Antibodies
14.4.2. Therapeutic Proteins
14.4.3. Vaccines
14.5. South America Bioengineered Protein Drugs Market Value Share Analysis, By Disease Condition
14.6. South America Bioengineered Protein Drugs Market Forecast, By Disease Condition
14.6.1. Cancer
14.6.2. Diabetes
14.6.3. Autoimmune Disorder
14.6.4. Infectious Disease
14.6.5. Hematopoiesis
14.6.6. CVD
14.6.7. Neurodegenerative
14.7. South America Bioengineered Protein Drugs Market Value Share Analysis, by Country
14.8. South America Bioengineered Protein Drugs Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Bioengineered Protein Drugs Market Forecast, By Type
14.9.1. Monoclonal Antibodies
14.9.2. Therapeutic Proteins
14.9.3. Vaccines
14.10. Brazil Bioengineered Protein Drugs Market Forecast, By Disease Condition
14.10.1. Cancer
14.10.2. Diabetes
14.10.3. Autoimmune Disorder
14.10.4. Infectious Disease
14.10.5. Hematopoiesis
14.10.6. CVD
14.10.7. Neurodegenerative
14.11. Mexico Bioengineered Protein Drugs Market Forecast, By Type
14.11.1. Monoclonal Antibodies
14.11.2. Therapeutic Proteins
14.11.3. Vaccines
14.12. Mexico Bioengineered Protein Drugs Market Forecast, By Disease Condition
14.12.1. Cancer
14.12.2. Diabetes
14.12.3. Autoimmune Disorder
14.12.4. Infectious Disease
14.12.5. Hematopoiesis
14.12.6. CVD
14.12.7. Neurodegenerative
14.13. Rest of South America Bioengineered Protein Drugs Market Forecast, By Type
14.13.1. Monoclonal Antibodies
14.13.2. Therapeutic Proteins
14.13.3. Vaccines
14.14. Rest of South America Bioengineered Protein Drugs Market Forecast, By Disease Condition
14.14.1. Cancer
14.14.2. Diabetes
14.14.3. Autoimmune Disorder
14.14.4. Infectious Disease
14.14.5. Hematopoiesis
14.14.6. CVD
14.14.7. Neurodegenerative 
14.15. South America Bioengineered Protein Drugs Market Attractiveness Analysis
14.15.1. By Type
14.15.2. By Disease Condition
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Type Launches and Type Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Abbott India Ltd.;

15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Type Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Amgen, Inc.;
15.3.3. Bayer AG;
15.3.4. Biocon Ltd.;
15.3.5. Dr. Reddy’s Laboratories Ltd.;
15.3.6. Eli Lilly and Company;
15.3.7. F. Hoffmann Roche AG;
15.3.8. GlaxoSmithKline PLC;
15.3.9. Johnson & Johnson;
15.3.10. Merck & Co., Inc.;
15.3.11. Novartis International AG;
15.3.12. Panacea Biotec Ltd.;
15.3.13. ProBioGen AG
15.3.14. Reliance Life Sciences Pvt. Ltd
15.3.15. AbbVie Inc.
15.3.16. Sanofi S.A.
15.3.17. Novo Nordisk AG
15.3.18. ProBioGen AG
15.3.19. Fresenius Kabi USA

16. Primary Key Insights
  • INQUIRE BEFORE BUYING